About Us
Our Mission
NETRIS Pharma is dedicated to provide novel therapeutic solutions to patients suffering from cancer. We leverage our in-depth understanding of tumor evasion mechanisms to develop innovative treatments able to overcome resistance to current oncology treatments such as chemotherapy and immunotherapy.
Our Solution
Netrin-1 is a novel target in oncology, known to regulate cancer cell death, metastasis and resistance to treatments. NP137 is the premier anti-Netrin-1 monoclonal antibody in clinical development having demonstrated over more than 300 patients an excellent safety profile and anti-tumoral activity in several solid tumors. The product is currently being investigated in different cancer types of high unmet medical need to become a new solution for patients.
Our Network of Excellence
The company is the First spin-off of the Centre Léon Bérard, the largest Comprehensive Cancer Research Center in France. Hosted at the heart of the CLB in Lyon, NETRIS Pharma benefits from a privileged access to world class clinical and translational research facilities.
To accelerate the development of its pipeline, NETRIS Pharma collaborates with leading industry partners such as MSD and ORANO, as well as with world-renowned international research centers.
The quality of our approach has been recognized and supported by multiple awards and grants from European (Agence Nationale de la Recherche (RHU), INSERM, Banque Publique d’Investissement (BPI), Eurostar program, FP7 EIC-EISMEA) and US (Pancan) organizations.
Our Team
Our team combines complementary experience in fundamental and translational research, clinical development and corporate developments.
